Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Radcliffe Department of Medicine researcher Dr Betty Raman is leading a new phase 2a clinical trial to investigate whether a drug could treat the fatigue and muscle weakness experienced by many patients who have recovered from COVID. The drug, AXA1125, is developed by the US-based biotechnology company Axcella Therapeutics.

Schematic drawing showing sitting male figure with mask, surrounded by COVID like particles.

More than 240 million cases of COVID-19 have been reported worldwide to date, and a US study estimated that a nearly a quarter of US COVID-19 patients suffer long-term effects from the virus. This constellation of long term symptoms is collectively called long COVID.

Fatigue and muscle weakness is the commonly reported symptom in long COVID patients, and a dysfunction in the mitochondria (the cell’s energy factories) is one potential explanation for these symptoms.

“Long COVID is having a truly devastating impact on countless people around the world, leaving many with a sense of hopelessness. It is widely recognized that mitochondrial dysfunction may contribute to the profound fatigue associated with this condition,” said lead researcher Dr. Betty Raman, British Heart Foundation Oxford Centre for Research Excellence Transition Clinical Intermediate Fellow (Radcliffe Department of Medicine). “With no approved Long COVID therapies, the need for continued innovation is urgent. I am pleased to be leading an investigation of AXA1125 to understand its potential to restore cellular energetics and address patients’ needs.”

Read the full story on the Radcliffe Department of Medicine website

The story is also featured on the University of Oxford website

 

 

Similar stories

Cancer Research UK to invest £11 million into cancer science in Oxford

A £11 million Cancer Research UK investment has been awarded to the University of Oxford and Oxford-based NHS to catalyse the translation of its world-leading cancer research for patient benefit.

Review highlights risk factors associated with violence in schizophrenia

Researchers at Oxford University’s Department of Psychiatry have found that people with schizophrenia and related disorders are at higher-than-average risk of perpetrating violence, but that the overall risk remains low (less than 1 in 20 in women, and less than 1 in 4 for men over a 35-year period for violent arrests and crimes).

An estimated 1.2 million people died in 2019 from antibiotic-resistant bacterial infections

First comprehensive analysis of global impact of antimicrobial resistance (AMR) estimates resistance itself caused 1.27 million deaths in 2019 - more deaths than HIV/AIDS or malaria - and that antimicrobial-resistant infections played a role in 4.95 million deaths.

Attention and memory deficits persist for months after recovery from mild Covid

Researchers from Oxford’s Department of Experimental Psychology and Nuffield Department of Clinical Neurosciences have shown that people who have had Covid but don’t complain of long Covid symptoms in daily life nevertheless can show degraded attention and memory for up to 6-9 months.

Plaster cast or metal pins to treat a broken wrist? The results are in.

An Oxford study published in The BMJ has found the use of metal K-wires (commonly known as ‘pins’) to hold broken wrist bones in place while they heal are no better than a traditional moulded plaster cast.

New book expands the horizons of brain research

A pioneering book from Professor Zoltán Molnár and Yale Professors Tamas Horvath and Joy Hirsch to be released on 1 February 2022 addresses the fundamental relationship between the body, brain and behaviour.